Top

Osteoporosis International

Published in:

01-12-2020 | Dapagliflozin | Original Article

Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials

Authors: B-B. Qian, Q. Chen, L. Li, C-F. Yan

Published in: Osteoporosis International | Issue 12/2020

Abstract

Summary

This study analyzed the effects of combination therapy with sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin on fracture risk. Summarizing available randomized controlled trials, we found that SGLT2is combined with metformin therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.

Introduction

No study is available evaluating the association between sodium-glucose transporter-2 inhibitors (SGLT2is) in combination with metformin use and fracture risk. Our study aimed to investigate the fracture risk of combination therapy with SGLT2is and metformin in patients with type 2 diabetes mellitus (T2DM).

Methods

PubMed, Embase, ClinicalTrials.gov site, and the Cochrane Library databases were scrutinized for all eligible randomized controlled trials (RCTs). The summarized odds ratios (ORs) and their 95% confidence intervals (CI) were calculated using Review Manager 5.3 software.

Results

A total of 25 RCTs involving 19,500 participants with T2DM were included in our studies. There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group. SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM (OR = 0.97, 95% CI 0.71–1.32). After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable.

Conclusion

SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.

Prospero registration number

CRD42020168435.

Available only for authorised users

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9^th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843CrossRefPubMed

Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F (2012) Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27:319–332. https://doi.org/10.1007/s10654-012-9674-xCrossRefPubMedPubMedCentral

Mitchell A, Fall T, Melhus H, Wolk A, Michaëlsson K, Byberg L (2018) Type 2 diabetes in relation to hip bone density, area, and bone turnover in Swedish men and women: a cross-sectional study. Calcif Tissue Int 103:501–511. https://doi.org/10.1007/s00223-018-0446-9CrossRefPubMedPubMedCentral

Napoli N, Chandran M, Pierroz DD et al (2017) Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 13:208–219. https://doi.org/10.1038/nrendo.2016.153CrossRefPubMed

Bucala R, Vlassara H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875–888. https://doi.org/10.1016/0272-6386(95)90051-9CrossRefPubMed

Chen H-H, Horng M-H, Yeh S-Y, Lin IC, Yeh CJ, Muo CH, Sung FC, Kao CH (2015) Glycemic control with thiazolidinedione is associated with fracture of T2DM patients. PLoS One 10:e0135530. https://doi.org/10.1371/journal.pone.0135530CrossRefPubMedPubMedCentral

Zhang Y, Chen Q, Liang Y, Dong Y, Mo X, Zhang L, Zhang B (2019) Insulin use and fracture risk in patients with type 2 diabetes: a meta-analysis of 138,690 patients. Exp Ther Med 17:3957–3964. https://doi.org/10.3892/etm.2019.7461CrossRefPubMedPubMedCentral

Zhang Z, Cao Y, Tao Y, E M, Tang J, Liu Y, Li F (2019) Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract 159:107990. https://doi.org/10.1016/j.diabres.2019.107990CrossRefPubMed

Schwartz AV (2017) Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia 60:1170–1179. https://doi.org/10.1007/s00125-017-4283-6CrossRefPubMed

10.

Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29:2639–2644. https://doi.org/10.1007/s00198-018-4649-8CrossRefPubMed

11.

Bahrambeigi S, Yousefi B, Rahimi M, Shafiei-Irannejad V (2019) Metformin; an old antidiabetic drug with new potentials in bone disorders. Biomed Pharmacother 109:1593–1601. https://doi.org/10.1016/j.biopha.2018.11.032CrossRefPubMed

12.

Salari-Moghaddam A, Sadeghi O, Keshteli AH, Larijani B, Esmaillzadeh A (2019) Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos Int 30:1167–1173. https://doi.org/10.1007/s00198-019-04948-1CrossRefPubMed

13.

American Diabetes Association (2020) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 43:S98–S110. https://doi.org/10.2337/dc20-S009CrossRef

14.

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-XCrossRefPubMed

15.

Kuchay MS, Farooqui KJ, Mishra SK, Mithal A (2020) Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Adv Exp Med Biol. https://doi.org/10.1007/5584_2020_479

16.

Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493. https://doi.org/10.2337/dci19-0066CrossRefPubMed

17.

Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8–10. https://doi.org/10.1016/S2213-8587(14)70227-XCrossRefPubMed

18.

Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44–51. https://doi.org/10.1210/jc.2015-1860CrossRefPubMed

19.

Thrailkill KM, Bunn RC, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK Jr, Fowlkes JL (2017) Corrigendum to “SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice” [Bone 82 (2016) 101-107]. Bone 105:316. https://doi.org/10.1016/j.bone.2016.11.021CrossRefPubMed

20.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925CrossRefPubMed

21.

Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971. https://doi.org/10.1038/ki.2013.356CrossRefPubMed

22.

Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG (2019) Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 21:1027–1036. https://doi.org/10.1111/dom.13631CrossRefPubMedPubMedCentral

23.

Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159–169. https://doi.org/10.1111/dom.12189CrossRefPubMed

24.

Lu C-H, Min KW, Chuang L-M, Kokubo S, Yoshida S, Cha BS (2016) Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig 7:366–373. https://doi.org/10.1111/jdi.12422CrossRefPubMed

25.

Yang W, Han P, Min K-W, Wang B, Mansfield T, T'Joen C, Iqbal N, Johnsson E, Ptaszynska A (2016) Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J Diabetes 8:796–808. https://doi.org/10.1111/1753-0407.12357CrossRefPubMed

26.

Lee SY, Park MS, Kwon S-S, Sung KH, Jung HS, Lee KM (2016) Influence of ankle fracture surgery on glycemic control in patients with diabetes. BMC Musculoskelet Disord 17:137. https://doi.org/10.1186/s12891-016-0987-xCrossRefPubMedPubMedCentral

27.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744CrossRefPubMed

28.

Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G (2016) Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:157–166. https://doi.org/10.1210/jc.2015-3167CrossRefPubMed

29.

Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program. Diabetologia 62:1854–1867. https://doi.org/10.1007/s00125-019-4955-5CrossRefPubMedPubMedCentral

30.

Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, Bernstein S, Courville AB, Collins MT, Rother KI, Taylor SI (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:e99123. https://doi.org/10.1172/jci.insight.99123CrossRefPubMedCentral

31.

Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML (2012) Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant 27:3725–3731. https://doi.org/10.1093/ndt/gfs412CrossRefPubMed

32.

Lee PC, Ganguly S, Goh S-Y (2018) Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 19:1630–1641. https://doi.org/10.1111/obr.12755CrossRefPubMed

33.

Shapses SA, Riedt CS (2006) Bone, body weight, and weight reduction: what are the concerns? J Nutr 136:1453–1456. https://doi.org/10.1093/jn/136.6.1453CrossRefPubMed

34.

Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 33. https://doi.org/10.1002/dmrr.2903

35.

Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18:1199–1206. https://doi.org/10.1111/dom.12742CrossRefPubMed

36.

Li X, Li T, Cheng Y, Lu Y, Xue M, Xu L, Liu X, Yu X, Sun B, Chen L (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev 35:e3170. https://doi.org/10.1002/dmrr.3170CrossRefPubMed

37.

Azharuddin M, Adil M, Ghosh P, Sharma M (2018) Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 146:180–190. https://doi.org/10.1016/j.diabres.2018.10.019CrossRefPubMed

38.

Cheng L, Li Y-Y, Hu W, Bai F, Hao HR, Yu WN, Mao XM (2019) Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab 45:436–445. https://doi.org/10.1016/j.diabet.2019.01.010CrossRefPubMed

39.

Schmedt N, Andersohn F, Walker J, Garbe E (2019) Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 21:52–60. https://doi.org/10.1111/dom.13480CrossRefPubMed

40.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720CrossRefPubMed

41.

Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.xCrossRefPubMed

42.

Thrailkill KM, Nyman JS, Bunn RC, Uppuganti S, Thompson KL, Lumpkin CK Jr, Kalaitzoglou E, Fowlkes JL (2017) The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 94:141–151. https://doi.org/10.1016/j.bone.2016.10.026CrossRefPubMed

Title: Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
Authors: B-B. Qian
Q. Chen
L. Li
C-F. Yan
Publication date: 01-12-2020
Publisher: Springer London
Keywords: Dapagliflozin
Metformin
Diabetes
Canagliflozin
Type 2 Diabetes
Published in: Osteoporosis International / Issue 12/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05590-y

At a glance: The STEP trials

Springer Medicine

Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials

Abstract

Summary

Introduction

Methods

Results

Conclusion

Prospero registration number

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Prospero registration number

Please log in to get access to this content

Other articles of this Issue 12/2020

Relationship between visceral adipose tissue and bone mineral density in Australian baby boomers

Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease

Bilateral atypical ulnar fractures occurring after long-term treatment with bisphosphonate for 7 years and with teriparatide for 2 years: a case report